Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up.
The aim of this trial was to examine the effects after 2 years of a single intravesical botulinum toxin-A injection (BTX-A). This prospective, observational study was conducted using urodynamic measurements and quality of life (QoL) assessment to document the effect after 2 years of a single 100 I.U. injection of BTX-A into the vesical detrusor muscle. Twenty-six patients were followed up for 2 years after a first intravesical BTX-A injection. Of these 26 patients, one was a primary failure, three were lost to follow-up, and 11 patients had a repeated injection at 5-26 months (one patient had a third injection). Seven of the remaining 11 patients in the single injection group were recommended repeated injection or another treatment, and four required no other treatment. In conclusion, 2 years after a single BTX-A injection statistically significant differences in urodynamics and an improvement in QoL could still be demonstrated.
Kuschel
Stefanie
S
Department of Obstetrics and Gynecology, Cantonal Hospital Lucerne, Lucerne, Switzerland. Stefanie.Kuschel@ksl.ch
Werner
Matthias
M
Schmid
Daniel Max
DM
Faust
Elke
E
Schuessler
Bernhard
B
D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D011788:Quality of Life; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A